PER 1.18% 8.4¢ percheron therapeutics limited

Ann: Quarterly Update and Appendix 4C, page-4

  1. 3,220 Posts.
    lightbulb Created with Sketch. 259
    Some point extracted from today’s ann that should make the market (hopefully regardless diamond’s effect)) bit more confident:

    1- Upon commencement of the Company’s pivotal trial of ATL1102 in Europe, Dr Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring
    ***announcing something like that in my view it looks agreement with EMA for 2b is given for granted.***

    2- Following the recently reported positive clinical trial results in the Phase II clinical trial of ATL1102, the Company is actively exploring clinical development opportunities where inflammation plays a key role in disease progression.
    ATL1102 was previously shown to be highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients.
    ***also here management sound due to results sound very confident to explore applications ***

    Now we need the much waited announcement referring DMD final report/results...
    Last edited by imperatore: 21/04/20
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.4¢
Change
-0.001(1.18%)
Mkt cap ! $75.72M
Open High Low Value Volume
8.4¢ 8.4¢ 8.3¢ $3.097K 37.23K

Buyers (Bids)

No. Vol. Price($)
1 29206 8.3¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 118557 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.